President and CEO Mike Carrel outlined the company’s strategy and growth outlook during a presentation and Q&A at a JPMorgan ...
The Farapoint device adds another tool to the company’s pulsed field ablation portfolio that could help increase or sustain ...
The Atrial Fibrillation (AFib) market is currently undergoing substantial expansion, fueled by several converging factors ...
This week, Bobbi Conner talks with Dr. Rachel Kaplan about managing atrial fibrillation. Dr. Kaplan is an Associate Professor ...
Partnership expands access to clinically proven esophageal protection for atrial fibrillation ablation across federal ...
PHILADELPHIA (WPVI) -- Most of us have heard of atrial fibrillation, commonly called AFib. The airwaves are filled with commercials for treatments. A Roxborough woman shared her struggle with it, and ...
Abbott (ABT)'s Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – ...
On Monday, the U.S. Food and Drug Administration (FDA) approved Abbott Laboratories’ (NYSE: ABT) Volt PFA System to treat patients battling atrial fibrillation (AFib). AFib is the most common type of ...
After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an international ...
AtriCure (NASDAQ:ATRC) is one of the most promising mid-cap healthcare stocks under $50. On December 16, J.P. Morgan analyst Lilia-Celine (Lily) reiterated her bullish stance on AtriCure (NASDAQ:ATRC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback